When talking about the pharmaceutical and healthcare sectors, Abbott Laboratories (ABT) is one of the few big names that will always attract a lot of attention. Abbott is one of the largest manufacturers of pharmaceutical products, and is one of the most popular stock options available in the market. But why is this so? The basic reason for its popularity stems from the manner in which the stock has grown over the years. Revenues and profits have increased over time, and the stock has offered steady earnings and returns for its investors.
Abbott has managed to maintain its wide competitive moat in the pharmaceutical industry with the introduction of new innovative products and the establishment of new strategic alliances. The company has recently announced the development of a range of new products under the EAS Sports Nutrition Brand. These new drugs will enhance the post-workout recovery of athletes, increasing overall muscle efficiency and allowing them to meet their fitness goals more effectively.
Furthermore, in collaboration with Eisai, Abbott Japan has recently cleared the preconditions that were necessary to acquire the approval of Humira, a completely human Anti-TNF-Alpha Monoclonal Antibody. This is a significant positive development for Abbott as it will allow the company to strengthen its position in integrative neuroscience and neurological and psychiatric medicines.
Abbott has also broadened its alliance with St. Jude Medical (STJ) for the development of a new range of cardiovascular products.. To continue reading, click here.